Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
17.41
+0.15 (0.87%)
At close: Dec 5, 2025, 4:00 PM EST
17.07
-0.34 (-1.95%)
After-hours: Dec 5, 2025, 7:48 PM EST
Monte Rosa Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Monte Rosa Therapeutics stock have an average target of 15, with a low estimate of 13 and a high estimate of 17. The average target predicts a decrease of -13.84% from the current stock price of 17.41.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Monte Rosa Therapeutics stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Hold Maintains $10 → $13 | Hold | Maintains | $10 → $13 | -25.33% | Nov 7, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $11 → $10 | Hold | Maintains | $11 → $10 | -42.56% | Mar 21, 2025 |
| Wedbush | Wedbush | Buy Maintains $15 → $17 | Buy | Maintains | $15 → $17 | -2.35% | Mar 21, 2025 |
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $14 → $11 | Buy → Hold | Downgrades | $14 → $11 | -36.82% | Dec 19, 2024 |
| Wedbush | Wedbush | Buy Reiterates $11 | Buy | Reiterates | $11 | -36.82% | Sep 12, 2024 |
Financial Forecast
Revenue This Year
137.27M
from 75.62M
Increased by 81.52%
Revenue Next Year
52.47M
from 137.27M
Decreased by -61.78%
EPS This Year
-0.29
from -0.98
EPS Next Year
-1.53
from -0.29
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 169.0M | 200.6M | ||||
| Avg | 137.3M | 52.5M | ||||
| Low | 105.8M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 123.4% | 46.1% | ||||
| Avg | 81.5% | -61.8% | ||||
| Low | 40.0% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 0.04 | -0.14 | ||||
| Avg | -0.29 | -1.53 | ||||
| Low | -0.43 | -1.99 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.